Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Siemens Healthineers – ADVIA Centaur® SARS-CoV-2 Total (COV2T) assay

The ADVIA Centaur® SARS-CoV-2 Total (COV2T) assay is a chemiluminescent immunoassay intended for qualitative detection of total antibodies (including IgG and IgM) to SARS-CoV-2 in human serum and plasma (EDTA and lithium heparin) using the ADVIA Centaur® XP & XPT systems. Siemens has over 2,000 fully automated immunoassay analyzers in hospitals and mid- to high-volume reference laboratories across all 50 states. The analyzers include the Atellica® IM which can run up to 440 tests/hour with result in 10 minutes and the ADVIA Centaur® XP & XPT analyzers, which can test up to 240 samples/hour with result in 18 minutes.

Emergency Use Authorization

On July 31, 2020, FDA issued an Emergency Use Authorization (EUA) to allow Siemens Healthineers’ ADVIA Centaur® SARS-CoV-2 IgG to (COV2G) to be used to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.  Emergency use of this test is limited to authorized laboratories.


  • This page last reviewed: October 26, 2020